Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FFAR4 | Q5NUL3 | 4/20 | 0.39 |
| ▸ | GRM5 | P41594 | 2/20 | 0.36 |
| ▸ | PRMT5 | O14744 | 4/20 | 0.33 |
| ▸ | NPY2R | P49146 | 1/20 | 0.32 |
| ▸ | FEN1 | P39748 | 2/20 | 0.32 |
| ▸ | ALOX5AP | P20292 | 1/20 | 0.32 |
| ▸ | PDE3B | Q13370 | 1/20 | 0.32 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25819403 | 0.91 | FFAR4 (0.42) | FFAR4GRM5PRMT5NPY2R | |
| SCHEMBL25031334 | 0.89 | FFAR4 (0.47) | FFAR4GRM5FEN1ALOX5AP | |
| SCHEMBL31382298 | 0.87 | FFAR4 (0.39) | FFAR4GRM5PRMT5 | |
| SCHEMBL25823605 | 0.86 | FFAR4 (0.38) | FFAR4GRM5PRMT5NPY2R | |
| SCHEMBL31018330 | 0.86 | FFAR4 (0.38) | FFAR4GRM5PRMT5NPY2R | |
| SCHEMBL29013184 | 0.85 | GRM5 (0.38) | FFAR4GRM5PRMT5NPY2RPDE3B | |
| SCHEMBL25031311 | 0.83 | FFAR4 (0.48) | FFAR4GRM5FEN1ALOX5AP | |
| SCHEMBL30479064 | 0.83 | FFAR4 (0.48) | FFAR4GRM5FEN1ALOX5AP | |
| SCHEMBL24753633 | 0.83 | HTR1A (0.46) | FFAR4PRMT5 | |
| SCHEMBL25938824 | 0.83 | GRM5 (0.40) | FFAR4GRM5NPY2RPDE3BPDE3A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-116322700-B | Novel PLK1 degradation inducing compounds | 厄普特拉株式会社 | 2024-08-20 | — | — | CN | disclosed |
| US-11912710-B2 | Substituted pyrimido[4,5-b][1,4]diazepines as PLK1 degradation inducers | UPPTHERA, INC. (KR) | 2024-02-27 | — | — | US | disclosed |
| US-20230219966-A1 | NOVEL PLK1 DEGRADATION INDUCING COMPOUND | UPPTHERA, INC. (KR) | 2023-07-13 | — | — | US | disclosed |
| US-20230219966-A1 | NOVEL PLK1 DEGRADATION INDUCING COMPOUND | UPPTHERA, INC. (KR) | 2023-07-13 | — | — | US | disclosed |
| CN-116322700-A | Novel PLK1 degradation inducing compounds | 厄普特拉株式会社 | 2023-06-23 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230219966-A1 | NOVEL PLK1 DEGRADATION INDUCING COMPOUND | PLK1, BUB1B, BUB1 | FFAR4 4754/4885GRM5 3397/4885PRMT5 1663/4885 |
| US-11912710-B2 | Substituted pyrimido[4,5-b][1,4]diazepines as PLK1 degradation inducers | PLK1, BUB1B, BUB1 | FFAR4 4733/4885GRM5 1390/4885PRMT5 1244/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.